Azelaic Acid Exerts Antileukemic Activity in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an acute leukemia common in most adults; its prevalence intensifies with age. The overall survival of AML is very poor because of therapeutic resistance. Azelaic acid (AZA) is non-toxic, non-teratogenic, and non-mutagenic and its antitumor effect on various tumor cell...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2017-06, Vol.8, p.359-359
Main Authors: Pan, Yunbao, Liu, Dong, Wei, Yongchang, Su, Dan, Lu, Chenyang, Hu, Yanchao, Zhou, Fuling
Format: Article
Language:English
Subjects:
acute myeloid leukemia
AKT
Azelaic acid
Jab1
Pharmacology
targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute myeloid leukemia (AML) is an acute leukemia common in most adults; its prevalence intensifies with age. The overall survival of AML is very poor because of therapeutic resistance. Azelaic acid (AZA) is non-toxic, non-teratogenic, and non-mutagenic and its antitumor effect on various tumor cells is well established; Nonetheless, its therapeutic effects in AML cells are largely unknown. In this study, it was shown that AZA significantly inhibits the cell viability and induces apoptosis in AML cells in a dose-dependent manner. Additionally, AZA suppressed the expression of phosphorylated Akt, Jab1 and Trx, and this suppression was enhanced by treatment with Jab1 siRNA. Furthermore, AZA sensitized AML cells to Ara-c chemotherapy. The suppressive effect of AZA on tumor growth was examined by subcutaneously inoculated AML cells in a tumor model using nude mice. These findings indicate that AZA is useful as an effective ingredient in antineoplastic activity.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2017.00359